(Q38101134)

28 August 2017

title

Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate (English)

1 reference

28 August 2017

1 reference

Rafael Maldonado

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

23 April 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

8

1 reference

28 August 2017

page(s)

1001-1014

1 reference

The effect of ADHD on the life of an individual, their family, and community from preschool to adult life

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Globalisation of international health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

The economic impact of attention-deficit/hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Stages of faith and identity: birth to teens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Osmotic, controlled-release methylphenidate for the treatment of ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Review and comparison of the long acting methylphenidate preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

A postmarketing clinical experience study of Metadate CD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Does a morning dose of Methylphenidate Retard reduce hyperkinetic symptoms in the afternoon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

A Double-Blind, Randomized, Placebo/Active Controlled Crossover Evaluation of the Efficacy and Safety of Ritalin®LA in Children with Attention-Deficit/Hyperactivity Disorder in a Laboratory Classroom Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

A Randomized, Single-Blind, Substitution Study of OROS Methylphenidate (Concerta) in ADHD Adults Receiving Immediate Release Methylphenidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.786041

10.1517/17425255.2013.786041

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference